Sulforaphane and Broccoli Sprouts: From Petri Dish to Real Outcomes

Sulforaphane has more peer-reviewed Nrf2-activation papers than almost any other food compound, but only a handful of human clinical outcome trials. The signal in cell culture and rodent cancer-prevention models is unusually strong; in humans, the strongest data is in autism spectrum behavior and air-pollution detoxification. Most other claims — heart disease, dementia, autoimmunity — sit in mechanism-only territory. The single most useful insight for consumers is the myrosinase problem: most sulforaphane supplements deliver a precursor that the human gut converts inefficiently.

Where sulforaphane comes from

Sulforaphane is the active form of glucoraphanin, a glucosinolate concentrated in broccoli, especially in 3-day-old broccoli sprouts. The conversion requires myrosinase, an enzyme released when the plant is chewed, blended, or chopped. Three-day-old sprouts contain 10–100 times more glucoraphanin than mature broccoli, which is why they're the dominant source in research protocols.

Cooking destroys plant myrosinase. Boiled broccoli still releases sulforaphane via gut bacteria with myrosinase activity, but inefficiently — bioavailability drops to 10–20 percent of raw or lightly steamed broccoli. The "hack" of adding mustard powder to cooked broccoli works because mustard seed retains myrosinase and donates it to the dish.

The autism trial that put sulforaphane on the map

Singh and colleagues at MassGeneral and Johns Hopkins published a small but rigorous RCT in 2014: 44 young men with moderate-to-severe autism spectrum disorder received 50–150 µmol/day of sulforaphane (from broccoli sprout extract) or placebo for 18 weeks. The treatment group showed significant improvement on the Aberrant Behavior Checklist and Social Responsiveness Scale. A follow-up trial by the same group in 2017 replicated some, though not all, of the behavioral effects. The precise mechanism remains unclear — heat-shock and Nrf2 pathway activation are leading candidates.

Subsequent autism trials have been mixed. A 2020 trial by Bent et al. (n=15) found no clinical effect at lower doses. The Singh result is the most cited evidence for a sulforaphane behavioral benefit and it has held up in two of four replications. The case is "promising but not closed," and parents enrolling children in trials should make decisions with their clinician rather than self-dosing.

Air pollution and chemoprevention

The Qidong (China) intervention trials are some of the best-designed sulforaphane studies in humans. Egner and Kensler's group ran multiple trials in heavily air-polluted regions, showing that broccoli sprout beverage accelerated urinary excretion of benzene and acrolein metabolites by 50–60 percent. This is mechanistic outcome data, not "fewer cancers" data, but the consistency across trials and the dose-response are striking. The same group's earlier work in Qidong showed reduced aflatoxin-DNA adducts.

Whether faster phase-II conjugation translates to lower long-term cancer risk remains unproven by hard endpoints. The chemoprevention case is biologically reasonable; the trial duration to test it adequately would be measured in decades.

Bioavailability and the myrosinase problem

If your supplement label says "broccoli extract" or "glucoraphanin" without explicit myrosinase content, expect 5–15 percent bioavailability. Products that include "active myrosinase" or are made from sprout-derived sulforaphane already in the active form (often labeled "stabilized sulforaphane") deliver 30–70 percent. Cooking sprouts at home for sulforaphane is generally less reliable than buying a standardized extract — sprout glucoraphanin content varies four-fold between batches.

The dose used in most positive trials is 50–100 µmol/day of sulforaphane (the active compound), which corresponds to roughly 25–50 g of fresh broccoli sprouts or a standardized extract delivering that amount. This is more than most people will eat as food on a daily basis.

Practical guidance

For someone with a specific clinical reason — a child enrolled in an autism trial, a person with a high air-pollution exposure, a participant in a chemoprevention study — sulforaphane has reasonable supporting evidence. For general "antioxidant" or longevity supplementation, the evidence is mechanistic, not outcome-based. Side effects in trials have been minimal: GI symptoms in roughly 10 percent of users at high doses.

The most defensible everyday strategy is dietary: a portion of lightly steamed broccoli or a small handful of broccoli sprouts several times per week, with mustard added if cooked. The supplement form is appropriate when the dose required exceeds what's practical from food, but read the label carefully — products without active myrosinase or stabilized sulforaphane are likely under-dosing the active compound regardless of what the front of the bottle promises.